



In the specification:

Please amend page 3, line 31 (paragraph [0017]) as follows:

In U.S. patent 6,126,920 the nature of the propellant is not discussed but two commercial products based on this patent, Luxi~~q~~LUXIQ® and Olux~~q~~OLUX® (Connetics®, Palo Alto, CA, USA), use a butane/propane mixture as a propellant and have no CFC based propellant.

Please amend page 27, line 2 (paragraph [0144]) as follows:

In order to ascertain that a composition of the present invention is not buffered despite the addition of a weak acid, the titration behavior of composition II (a) was compared to that of an identical composition devoid of lactic acid (b), and two samples of commercially available Olux~~q~~OLUX® Foam-foam containing 0.05% clobetasol propionate both having an identical expiry date more than a year from the time the stability evaluation was performed: batch # D3A003 manufactured by DPT Laboratories, Ltd. (San Antonio, Texas, USA) (c) and batch # 2E441 manufactured by CCL Pharmaceuticals (Cheshire, United Kingdom) (d).

Please amend page 27, line 16 (paragraph [0146]) as follows:

In Figure 1, the results of direct titration of a clobetasol propionate composition acidified according to the teachings of the present invention (a), a non-acidified clobetasol propionate composition having pH 7.0 (b) and a buffered prior art clobetasol propionate composition (c) are compared. From these results it is clear that the composition of the present invention is not buffered.

Please amend page 27, line 21 (Paragraph [0147]) as follows:

In Figure 2, the results of back titration of a clobetasol propionate composition acidified according to the teachings of the present invention (a), a non-acidified clobetasol propionate composition having pH 7.0 (b) and a buffered prior art

clobetasol propionate composition (d) are compared. From these results it is clear that the composition of the present invention is not buffered.

Please amend page 27, line 28 (paragraph [0149]) as follows:

The relative stability of composition II (a) was evaluated by comparison to an identical composition devoid of lactic acid (b), and two samples of commercially available OluxOLUX® Foam containing 0.05% clobetasol propionate both having an identical expiry date more than a year from the time the stability evaluation was performed: (d) batch # 2E441 manufactured by CCL Pharmaceuticals, Ltd. (Cheshire, United Kingdom) and (e) batch # 2L741 manufactured by MIZA Pharmaceuticals (UK) Ltd. (Cheshire, United Kingdom)